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Over the past 10 years, major progress has been made in the
pathogenesis of uric acid and calcium stones. These advances
have led to our further understanding of a pathogenetic link
between uric acid nephrolithiasis and the metabolic
syndrome, the role of Oxalobacter formigenes in calcium
oxalate stone formation, oxalate transport in Slc26a6-null
mice, the potential pathogenetic role of Randall’s plaque as a
precursor for calcium oxalate nephrolithiasis, and the role of
renal tubular crystal retention. With these advances, we may
target the development of novel drugs including (1) insulin
sensitizers; (2) probiotic therapy with O. formigenes,
recombinant enzymes, or engineered bacteria; (3) treatments
that involve the upregulation of intestinal luminal oxalate
secretion by increasing anion transporter activity (Slc26a6),
luminally active nonabsorbed agents, or oxalate binders; and
(4) drugs that prevent the formation of Randall’s plaque
and/or renal tubular crystal adhesions.
Kidney International (2009) 75, 585–595; doi:10.1038/ki.2008.626;
published online 10 December 2008
KEYWORDS: calcium oxalate; kidney stone; metabolic syndrome;
nephrolithiasis; uric acid
Calcium oxalate is the most prevalent type of kidney stone
disease in the United States and has been shown to occur in
70–80% of the kidney stone population.1 The prevalence of
recurrent calcium oxalate stones has progressively increased
in untreated subjects, approaching a 50% recurrence rate
over 10 years.2 The lifetime risk for kidney stone disease
currently exceeds 6–12% in the general population.3,4 In the
final quarter of the twenty-first century, the prevalence of
kidney stone disease increased in both gender and ethnicity.4
Although kidney stone nephrolithiasis is perceived as an
acute illness, there has been growing evidence that nephro-
lithiasis is a systemic disorder that leads to end-stage renal
disease.5–7 It is also associated with an increased risk of
hypertension,8–12 coronary artery disease,13,14 the metabolic
syndrome (MS),15–20 and diabetes mellitus.19–24 Nephro-
lithiasis without medical treatment is a recurrent illness with
a prevalence of 50% over 10 years.2 Nephrolithiasis has
remained a prominent issue that imposes a significant
burden on human health and is a considerable financial
expenditure for the nation. In 2005, based on inpatient and
outpatient claims, this condition was estimated to cost over
$2.1 billion.25 A novel strategy for the development of new
drugs has been hampered largely by the complexity of this
disease’s pathogenetic mechanism and its molecular
genetic basis. Our further understanding of these
underlying pathophysiologic mechanisms will be the key
step in developing more effective preventive and therapeutic
measures.
ETIOLOGIC MECHANISMS OF URIC ACID STONE FORMATION
Three major factors for the development of uric acid (UA)
stones are low urine volume, acidic urine pH, and
hyperuricosuria. However, abnormally acidic urine is the
principal determinate in UA crystallization. The etiologic
mechanisms for UA stone formation are diverse, and include
congenital, acquired, and idiopathic causes.26 The most
prevalent cause of UA nephrolithiasis is idiopathic. In its
initial description, the term ‘gouty diathesis’ was coined.27
The clinical and biochemical presentation of idiopathic UA
nephrolithiasis (IUAN) cannot be attributed to an inborn
error of metabolism 26,28,29 or secondary causes such as
chronic diarrhea,30 strenuous physical exercise,31 and a high
purine diet.32
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PHYSICOCHEMICAL CHARACTERISTICS OF URIC ACID
In humans and higher primates, UA is an end product of
purine metabolism. Owing to their lack of the hepatic
enzyme, uricase, which converts UA to soluble allantoin, their
serum and urinary levels of UA are considerably higher than
in other mammals.33 Normally, urinary UA solubility is
limited to 96 mg/l. In humans with a urinary UA excretion of
600 mg/day, this should generally exceed the limit of
solubility and susceptibility to precipitation.34 Moreover,
urine pH is another important factor in UA solubility. UA is a
weak organic acid with an ionization constant (pKa) of
5.5.35,36 Therefore, at a urine pH less than 5.5, the urinary
environment becomes supersaturated with sparingly soluble,
undissociated UA that precipitates to form UA stones21,37,38
(Figure 1).
EPIDEMIOLOGY OF URIC ACID NEPHROLITHIASIS AND THE
METABOLIC SYNDROME
The MS is an aggregate of features that increase the risk of
type 2 diabetes mellitus (T2DM) and atherosclerotic
cardiovascular disease.15–17 In a retrospective analysis a stone
registry in Dallas initially showed a high prevalence of
features of the MS in IUAN patients, leading to the
determination that patients with IUAN share characteristics
similar to those of the MS. Numerous epidemiologic studies
have shown that obesity, weight gain, and T2DM are
associated with an increased risk of nephrolithiasis.39,40
Despite the large sample size, stone composition was not
reported among these studies. This center first reported the
high prevalence of UA stones as the main stone constitute
found in T2DM. In addition, recent retrospective and cross-
sectional studies have noted an increased prevalence of UA
stones among obese and T2DM patients.23,41–44 However,
T2DM and a greater body mass index were shown to be
independent risk factors for nephrolithiasis.44
PATHOPHYSIOLOGY OF LOW URINE pH IN IDIOPATHIC URIC
ACID NEPHROLITHIASIS
The metabolic defect suspected for low urinary pH in UA
stone formation was described almost four decades ago.45
Defective ammoniagenesis or excretion was attributed as a
possible pathogenetic mechanism. Initial studies showing
abnormalities in glutamine metabolism, which resulted in the
impaired conversion of glutamine to a-ketoglutarate and
consequently resulted in reduced renal ammonium (NH4
þ )
excretion, were not supported by further investigation.46–49
Mechanistic studies, however, have shown that the two major
factors responsible for abnormally low urine pH are a
combination of defective NH4
þ excretion and increased net
acid excretion (NAE).
Defective ammonium excretion
Under normal circumstances, a tight acid–base balance is
maintained with a high capacity buffer, ammonia, (pKa 9.2),
which effectively buffers most protons while the remaining
protons are buffered by titratable acids. This process works to
sustain a normal urinary pH. In contrast, the defective NH4
þ
excretion in IUAN requires the urine to be buffered mainly by
titratable acids to maintain this equilibrium, thus promoting
an acidic urinary pH and providing an environment highly
conducive for UA precipitation (Figure 2).
Increased acid production alone may not be sufficient in
causing abnormally acidic urine, as the excreted acid is
neutralized by urinary buffers. Evidence of defective NH4
þ
excretion was provided in IUAN patients under a fixed,
metabolic diet.21,23 Therefore, an unduly acidic urine pH in
the IUAN population is not related to environmental factors
but it is, in part, related to the higher body weight in these
subjects.50 The defective NH4
þ production in these subjects
was further explored by the administration of an acute acid
load, which amplified the ammoniagenic effect21 (Figure 3).
Similar findings were also demonstrated in IUAN patients on
a random diet.22 Furthermore, it has been shown that in
normal persons, urinary pH and NH4
þ /NAE ratio falls
with increasing features of the MS, indicating that renal
H+ + Urate          Uric acid
pKa = 5.5
pH < 5.5
Undissociated uric acid
Uric acid or uric
acid/CaOx stones
Figure 1 | Physicochemical scheme for the development of
uric acid stones.
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Figure 2 | Mechanisms of urinary acidification.
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ammoniagenesis and low urine pH may be features of the
general MS and not IUAN specific.51
Several studies have provided evidence supporting a
relationship between UA nephrolithiasis, obesity, and insulin
resistance.21,23,41–44 The mechanistic connection between
peripheral insulin resistance, urinary pH, and NH4
þ , was
first demonstrated using the hyperinsulinemic-euglycemic
clamp technique in patients with IUAN.24 These studies
support the potential role of insulin resistance in an impaired
urinary NH4
þ excretion and low urinary pH. Insulin
receptors are expressed in various portions of the ne-
phron.52,53 Furthermore, in vitro studies have shown that
insulin has a stimulatory function in renal ammoniagen-
esis.54,55 In addition, NH4
þ secretion is regulated by the
sodium–hydrogen exchanger NHE3.56 As NHE3 has a key
function in the transport or trapping of NH4
þ in the renal
tubular lumen,56 insulin resistance may potentially lead to
defective renal NH4
þ excretion. One other plausible mechan-
ism may be substrate competition by substituting circulating
free fatty acid for glutamine, which is increased in the MS,
thereby reducing the proximal renal tubular cell utilization of
glutamine and renal ammoniagenesis.57
Increased net acid excretion
An elevated NAE may occur due to increased endogenous
acid production or because of dietary influences such as low
dietary alkali or the increased consumption of acid-rich
foods.36 Metabolic studies comparing subjects on fixed, low-
acid ash diets showed a higher NAE in IUAN patients
compared to control subjects, suggesting that endogenous
acid production may increase in IUAN 34 (Figure 4). In
addition, the urinary NAE for any given urinary sulfate
(a surrogate marker of acid intake) tended to be higher in
patients with T2DM.22 These studies also implied that the
pathophysiologic mechanism accounting for increased NAE
is related to obesity/insulin resistance. Supporting this
correlation, additional studies have shown increased organic
acid excretion with higher body weight and higher body
surface area.58,59 The nature of these putative organic anions
and their link to obesity and/or UA stones has not been fully
studied.
POTENTIAL ROLE OF RENAL LIPOTOXICITY
Under standard metabolic conditions, when caloric intake
and caloric utilization are well balanced, triglycerides
accumulate in adipocytes.60,61 A disequilibrium in this tight
balance leads to the accumulation of fat to non-adipocyte
tissues.61 This process of fat redistribution, termed lipotoxi-
city, typically affects tissues such as cardiac myocardial cells,
pancreatic b-cells, skeletal muscle cells, and parenchymal
liver cells.61–66
Cellular injury is primarily due to the accumulation of
nonesterified fatty acids and their toxic metabolites including
fatty acyl CoA, diacylglycerol, and ceramide.60,67,68 It has
been shown that fat redistribution is accompanied with
impaired insulin sensitivity,63 cardiac dysfunction,65 and
steatohepatitis.62,69 There is an emerging interest in the
role of renal lipotoxicity in the pathogenesis of renal
disease.67,70,71 A few studies have revealed a mechanistic link
between obesity, obesity-initiated MS, and chronic kidney
disease.70,71 Additional studies have shown a possible role of
sterol-regulating element-binding proteins in renal fat
accumulation and injury.72–74 At the present time, there is
insufficient data available to suggest whether renal lipotoxi-
city influences endogenous acid production and reduces
renal ammoniagenesis, consequently leading to abnormally
acidic urine.
From the above information, one may propose a three-hit
mechanism for the development of low urinary pH and the
propensity for UA stone formation. The first mechanism is
related to excessive dietary acid intake and/or increased
endogenous acid production. However, this alone may not be
sufficient in lowering urinary pH. Therefore, the second
mechanism is associated with defective NH4
þ excretion.
Together, these two defects lower urinary pH adequately
enough to convert urate salt into undissociated UA. This is
necessary but not sufficient for the formation of UA stones.
Finally, the possible absence of inhibitors or presence of
promoters of UA precipitation is operative in triggering UA
stone formation.
CALCIUM OXALATE NEPHROLITHIASIS
Although it affects both genders, calcium oxalate nephro-
lithiasis generally tends to occur in more men than women.
In the calcium oxalate stone former, urinary oxalate and
urinary calcium are equally conducive in raising urinary
calcium oxalate supersaturation.75 Hyperoxaluria is encoun-
tered in 8–50% of kidney stone formers.76–78 The main
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Figure 3 | Acute acid loading. Previously published in Sakhaee
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etiologic causes of hyperoxaluria can be classified into three
groups: (1) increased oxalate production as a result of an
inborn error in metabolism of the oxalate synthetic pathway,
(2) increased substrate provision from dietary oxalate-rich
foods or other oxalate precursors, and (3) increased intestinal
oxalate absorption.1 With the study of Oxalobacter formigenes
(OF)79,80 and the role of putative anion transporter Slc26a681
as potential tools in the treatment of primary hyperoxaluria,
our knowledge of the pathophysiologic mechanisms of
oxalate metabolism has advanced significantly over the
past decade.82
PHYSICOCHEMICAL PROPERTIES OF OXALATE
The human serum oxalate concentration ranges between 1
and 5 mM, however, due to water reabsorption in the
kidney, its concentration is 100 times higher in the urine.1,83
At a physiologic pH, oxalate will form an insoluble salt with
calcium. As the solubility of calcium oxalate in an
aqueous solution is limited to approximately 5 mg/l at a
pH of 7.0, assuming that normal urine volume ranges
between 1 and 2 l/day and normal urinary oxalate excretion is
less than 40 mg/day, normal urine is often supersaturated
with calcium oxalate. However, under normal conditions,
the blood is undersaturated with respect to calcium oxalate.
As seen in patients with primary hyperoxaluria and renal
insufficiency, when the serum oxalate concentration
increases to above 30 mM, the blood becomes supersaturated
with calcium oxalate.84 In the plasma, oxalate is not
significantly bound to protein and is freely filtered by the
kidneys. A recent study reported that urinary calcium is as
important as urinary oxalate in raising calcium oxalate
supersaturation.75
OXALATE HOMEOSTASIS
Hepatic production
In mammals, oxalate is an end product of hepatic
metabolism.79 The major precursor for hepatic oxalate
production is glyoxalate metabolism within hepatic peroxi-
somes. This metabolic conversion is mediated by enzyme
alanine–glyoxalate aminotransferase. Under normal circum-
stances, the metabolism of glyoxalate to glycolate and glycine
determines the conversion of glyoxalate to oxalate. Glyoxalate
is also metabolized to glycolate by enzyme D-glycerate
dehydrogenase, which has both glyoxalate/hydroxypyruvate
reductase activity.85 An inborn error in metabolism with
alanine–glyoxalate aminotransferase and glyoxalate/hydroxy-
pyruvate reductase deficiency leads to oxalate overproduc-
tion, which results in type 1 and type 2 primary
hyperoxaluria.79,81,85 Several other metabolic precursors of
oxalate metabolism, including the breakdown of ascorbic
acid, fructose, xylose, and hydroxyproline, have also been
incriminated. However, their influences on oxalate produc-
tion, under normal physiologic circumstances, have not been
fully accepted.86–88
Intestinal absorption
Dietary oxalate intake is important in urinary oxalate
excretion. The estimated intake of oxalate ranges between
50 and 1000 mg/day.77,78,89 Oxalate-rich foods primarily
include seeds, such as chocolate that is derived from tropical
cacao tree, and leafy vegetation, including spinach, rhubarb,
and tea. Approaching approximately 45%, the contribution
of dietary oxalate to urinary oxalate excretion has been shown
to be much higher than previously described.90 In addition,
with intestinal oxalate absorption ranging between 10 and
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72%, this relationship between oxalate absorption and
dietary oxalate intake has not been shown to be linear.90
In humans, the exact intestinal segment participating in
oxalate absorption has not been determined. Indirect
evidence suggests that oxalate absorption occurs throughout
a large segment of the small intestine. This has been proposed
as the main percentage of absorption occurs during the first
4–8 h after the ingestion of oxalate-rich foods.91–93 This
inference has been made based on the reported 5-h intestinal
transit time from the stomach to the colon. However, it has
also been suggested that the colon may also participate in
oxalate absorption, but to a lesser extent.93 In addition, the
paracellular intestinal oxalate flux has been suggested to
occur in the early segment of the small intestine largely due to
the negative intestinal luminal potential and higher luminal
oxalate concentration compared to the blood.94
Role of the putative anion exchange transporter Slc26a6
Recently, the putative anion exchange transporter Slc26a6 has
been shown to be involved in intestinal oxalate transport.82
The Slc26a6 is expressed in the apical portion of various
segments of the small intestine such as the duodenum,
jejunum, and ileum. It can also be found in the large
intestine, but to a smaller percentage.95 In vitro studies using
the Ussing chamber technique demonstrated defective net
oxalate secretion in mice with a targeted inactivation of the
Slc26a6.96 Moreover, in vivo studies in the Slc26a6-null mice
on a controlled oxalate diet reported high urinary oxalate
excretion, increased plasma oxalate concentration, and
decreased fecal oxalate excretion.96 The differences in urinary
oxalate excretion, plasma oxalate concentration, and fecal
oxalate excretion were abolished following a 7-day equilibra-
tion on an oxalate-free diet. These findings suggest that the
reduction of net oxalate secretion in Slc26a6-null mice
increases net oxalate absorption, raising plasma oxalate
concentrations and consequently raising urinary oxalate
excretion. This study concluded that the Slc26a6 anion
exchanger has a key function in urinary oxalate excretion.96
These results were also associated with bladder stones and
Yasue-positive crystals in the kidney. Staining of the kidney
specimen with Yasue stain demonstrated evidence of
birefringent crystal deposits in the luminal cortical collecting
ducts and, to a minimal extent, in the inner medullary
collecting ducts (IMCD). Calcium oxalate stones were found
in the renal pelvis and bladder. The renal tubular epithelial
cells were surrounded by lymphocytic infiltration and
distorted morphology. However, unlike with the kidneys in
idiopathic calcium oxalate stone formers, no abnormality was
found in the medullary interstitial space.
Role of O. formigenes
Among many other bacteria including Eubacterium
lentum, Enterococcus faecalis, Lactobacillus, Streptococcus
thermophilus, and Bifidobacterium infantis, OF have been
reported to degrade oxalate.94 OF was first isolated in
ruminates 97 and has since been found in many animal
species as well as in humans.98 However, OF is not found in
infancy. The bowel becomes colonized with this bacterium at
approximately 6–8 years of age. It decreases in later years and
may only be found in the feces of 60–80% of the adult
population.99
OF is a Gram-negative obligate anaerobe microorganism
that primary utilizes oxalate as a source of energy for cellular
biosynthesis.100 Through this electrogenic process, oxalate
enters the oxalobacter through an oxalate–formate antiporter.
It then utilizes its own enzymes, formyl CoA transferase and
oxalyl-CoA decarboxylase, to convert oxalate into formate
and CO2.
101 In this process, one proton is utilized and creates
a chemical gradiant due to the cell alkalinity. The electro-
chemical gradients created by these processes facilitate proton
entry and ATP synthesis101 (Figure 5).
The clinical importance of OF colonization is primarily
suggested for patients with recurrent calcium oxalate nephro-
lithiasis,102–104 in patients with enteric hyperoxaluria,105,106 and
in those with cystic fibrosis.107 Studies in patients with
urolithiasis and cystic fibrosis have shown that the prolonged
use of antibiotics may abrogate the bowel colonization of OF
and may irreversibly destroy these bacteria. Very recently, a
case–control study of 274 patients with recurrent calcium
oxalate stones and 259 normal subjects matched for age and
gender displayed that the prevalence of OF was significantly
lower in the stone formers. In this study, 17% of stone
formers were positive for OF vs 38% of normal subjects. This
relationship persisted with age, gender, race, ethnic back-
ground, region, and antibiotic use108 (Figure 6).
The colonization of OF may be regulated by dietary
oxalate intake. This has been shown in animal models
where a significant decrease in urinary oxalate resulted from
the administration or in the upregulation of OF coloniza-
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Figure 5 | Oxalate catabolism and energy conservation in
Oxalobacter formigenes.
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tion.102,109 It has been recently shown in rodents,
ex vivo using the Ussing chamber method, that the role of
OF in oxalate metabolism is not solely dependent on its
capacity to degrade intestinal luminal oxalate or to lower
mucosal to serosal oxalate flux, but also on its capacity to
stimulate the net intestinal oxalate secretion.110 Given this
experimental design, increased net oxalate secretion cannot
be explained by transepithelial oxalate gradients. One may
speculate that OF interacts with mucosal epithelial cells,
enhancing luminal oxalate secretion.
The result of these animal experiments has been recently
conveyed into human diseases.80 One such study conducted
in patients with type 1 primary hyperoxaluria, in subjects
with normal renal function, and in patients with chronic
renal insufficiency, reported the reduction of urinary oxalate
that ensued following the oral administration of OF.80 The
major drawbacks of the use of OF are (1) the lack of large,
long-term, controlled studies in calcium oxalate kidney stone
formers and in subjects with enteric hyperoxaluria, such as
patients with cystic fibrosis or those following a gastro-
intestinal bypass procedure; (2) the variable response to OF
administration; and (C) OF’s short life span on the complete
utilization of its primary nutrient source, oxalate. Future
long-term studies and the development of target drugs to
either upregulate the intestinal secretion of oxalate by
stimulating Slc26a6 provide the enzyme products of OF to
allow for its persistent oxalate-degrading capacity, provide
engineered bacteria that are not entirely dependent on
oxalate as a substrate for nutrients, or contain a luminally
active agent that binds intestinal luminal oxalate content are
necessary in overcoming these deficiencies.
Renal excretion
The kidney has an important function in oxalate excretion.
With impaired kidney function, plasma oxalate concentra-
tions progressively rise and result in kidney damage.
Eventually, with further impairment, there is a robust spike
in plasma oxalate concentration that exceeds its saturation in
the blood and thereby increases the risk of systemic tissue
oxalate deposition. It has been recently demonstrated that
Slc26a6 is also expressed in the apical portion of the proximal
renal tubule111 and influences the activity of various apical
anion exchangers.112 In Slc26a6-null mice, it has been shown
that Cl–oxalate exchange activity is completely inhibited, and
the activity of Cl/OH and Cl/HCO3 is significantly
diminished. However, the significance of this putative anion
transporter in calcium oxalate stone formation has not been
fully elucidated.
RANDALL’S PLAQUE IN THE PATHOGENESIS OF CALCIUM
OXALATE STONES
Several mechanisms have been proposed for the formation of
calcium stones. First, it has been suggested that the increased
supersaturation of stone-forming salts are responsible for the
process of homogenous nucleation in the lumen of the
nephron. This process, followed by crystal growth, ultimately
results in an obstruction in the distal nephron. Second, it has
been suggested that crystal forms in the renal tubular lumen
adhere to the luminal renal tubular cells. This adhesion then
induces renal cell injury resulting in the formation of a fixed
nuclei that interacts with the supersaturated urinary
environment and results in crystal growth. These processes
both lead to nephron obstruction and consequently result in
intratubular calcification.113 However, the theory of fixed and
free crystal growth attachments in the nephron has not been
fully described as a mechanism of kidney stone formation. As
occurs in intestinal bypass and cystine patients, if an
intraluminal crystal plug attachment occurs at the opening
of the Bellini duct, it is possible that this mineral plug can
protrude to the minor calyx, resulting in stone growth.
Dr Alexander Randall was the first to argue that
intraluminal plugging is an infrequent occurrence in kidney
stone formers.114 Conversely, he suggested that interstitial
calcium phosphate deposits are initial niduses that anchor
urinary crystals beneath the normal uroepithelial cells of the
renal papilla. The erosion of the overlying uroepithelium
exposes these deposits, referred to as plaques, to the
supersaturated urine that then propagate calcium oxalate
stones. He found these lesions to be interstitial as opposed to
intraluminal, and without any inflammatory reactions. He
also showed these deposits to be mainly found beneath the
tubular basement membrane and in the interstitial collagen.
Randall’s hypothesis was primarily disputed since it was
carried out in cadaveric kidney specimens and not in a
targeted kidney stone-forming population.114 His major
discovery, however, was a small stone propagated in the
renal pelvis that was attached to a calcium plaque found in
the papillae of the kidney.
Characteristics of the interstitial plaques
Randall’s initial observations were recently followed with
the development of modern techniques for determining
mineral composition. These techniques have been used to
Positive
(17%)
Oxalobacter formigenes status
Negative
(83%)
Positive
(38%)Negative(62%)
Recurrent CaOx
stone formers
(n = 247)
Non-stone formers
(n = 259)
Figure 6 | Oxalobacter formigenes in stool among patients
with recurrent calcium oxalate kidney stones and non-stone
formers. Previously published as a modification of information
obtained from Kaufman et al.108
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characterize the nature of crystals attached to these plaques
and to develop novel techniques to visualize Randall’s plaque
in vivo in patients with nephrolithiasis.115,116 An analysis of
over 5000 stones showed the main mineral composition of
interstitial plaque to be mainly carbapatite. However,
amorphous carbonated calcium phosphate, dosium hydrogen
urate, and UA were found to a smaller extent.117 Another
study utilizing m-CT determined that apatite crystal
surrounded by calcium oxalate was the main mineral
composition of Randall’s plaque.118
It was first shown that Randall’s plaques occur more
frequently in patients with kidney stones as compared to
non-stone formers undergoing an endoscopic evaluation.119
Furthermore, a relationship was found between metabolic
abnormalities in patients with calcium stones and the
number of plaques.120 The result of this study was reached
using digital video and endoscopic techniques to estimate
accurately the extent of Randall’s plaque in both calcium
stone-forming and non-stone-forming subjects.121 In this
study, the main biochemical profiles correlating with the
formation of interstitial plaque were urinary volume, urinary
pH, and urinary calcium excretion. Higher urinary calcium
and lower urinary volume showed an increased coverage of
the renal papilla with plaque. This study supports a
mechanistic relationship between water reabsorption in the
renal medulla and papilla with plaque formation. In addition,
a separate retrospective study, using nephroscopic papillary
mapping with representative still images and Moving Pictures
Expert Group movies in 13 calcium oxalate kidney stone
formers, determined the percent of plaque coverage to be
directly correlated with the number of kidney stones
formed.122
LOCALIZATION OF RANDALL’S PLAQUE
The basement membrane of thin descending loops of Henle
is the principal site of Randall’s plaque localization.115 The
thin descending limb basement membrane is made up of
collagen and mucopolysaccharides, which attract calcium and
phosphate ions.123 Once attracted to this protein matrix, the
crystallization processes begins. In the interaction following,
calcium phosphate crystals grow and propagate to the
surrounding collagen and mucopolysaccharide-rich renal
interstitium.124 This complex then makes its way through
the urothelium and serves as a nidus for calcium oxalate
deposition, ultimately resulting in calcium oxalate kidney
stone formation. Randall’s plaque has only been localized in
the basement membranes and in the interstitium. It has never
been found in the tubular lumen within epithelial cells or
vessels. Within the basement membrane, this plaque consists
of coated particles of overlying regions of crystalline material
and organic matrix116 (Figure 7).
MECHANISM OF PLAQUE FORMATION
The mechanism of interstitial plaque formation has not been
fully elucidated. Our limitations in this area are based on the
lack of availability of an animal model that mimics this
human disease. A few clinical studies have suggested a
correlation between urine volume, urinary calcium, and
severity of stone disease with the fraction of papillary
interstitium covered by Randall’s plaque.119–122 Although
this link is not causal, however, it indicates some correlation
between plaque formation and kidney stone disease in
idiopathic hypercalciuric patients. It is plausible to propose
that plaque formation in the thin descending limb of Henle
occurs because of an increase in interstitial calcium and
phosphate concentration as well as an increase in renal
papillary osmolality as a result of water reabsorption in this
nephron segmet.125 Moreover, whether increasing interstitial
fluid pH affects the abundance of plaque formation has been
suggested but has never been fully explored.116
ABSENCE OF RANDALL’S PLAQUE
Following gastric bypass surgery
Hyperoxaluria and calcium oxalate stones are a common
occurrence in patients following intestinal bypass surgery due
to morbid obesity.116,126 In these subjects, there is no plaque
observed in the renal papilla. However, crystal aggregates are
found in the IMCD. Moreover, in contrast to conditions in
idiopathic calcium oxalate stone formers, there is evidence of
renal IMCD cell injury, interstitial fibrosis, and inflammation
adjacent to the crystal aggregates. The IMCD crystal
aggregates are usually composed of apatite crystals. The
deposition of these apatite crystals occurs despite an acidic
urinary environment, implying that tubular pH may be
different from the final urinary pH.116,126
Figure 7 | Sites and characteristics of crystal deposition. A
transmission electron micrograph showing a crystalline structure
composed of concentric layers of crystalline material (light) and
matrix protein (dark). Previously published in Evan et al.127
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Brushite stone formers
In brushite stone formers, similar to calcium oxalate stone
formers following gastric bypass surgery, there is evidence of
cell injury and interstitial fibrosis in the IMCD adjacent to
apatite crystal deposits. Although brushite stone formers,
much like idiopathic calcium oxalate stone formers, have
plaque in the renal papilla, the stones have not been shown to
attach to the plaque.127 This may be, in part, due to clinical
and technical difficulties as the high burden of brushite
stones may affect the structural integrity of the renal papillae,
making it difficult to detect smaller stones that may be
attached to the plaque. In addition, the extent of Randall’s
plaque is minimal in brushite stone formers so attached
stones are not commonly anticipated. One important
predisposition to distortion of structural integrity of the
renal papillae in these subjects may be acquired and is related
to the number of shockwave lithotripsy in this popula-
tion.127,128
THE ROLE OF RENAL TUBULAR CRYSTAL RETENTION
Although the crystallization process is necessary, it alone is
not sufficient for the formation of kidney stones. Three
decades ago, it was initially proposed that the accumulation
of crystals in the renal calices are involved in the pathogenesis
of nephrolithiasis.129 It was further hypothesized that tubular
nephrocalcinosis is preceded by renal stone formation. This
scheme does not refute Randall’s theory that interstitial
nephrocalcinosis and plaque formation are precursors for the
development of kidney stones.114 However, it has become
increasingly recognized that both mechanisms may be
significant in the formation of kidney stones.130,131 The
further elaboration of these two pathogenic pathways is
important as stone formation may occur in the absence of
plaque in the kidney.132 Furthermore, experimental evidence
has suggested that crystal binding to the surface of the
regenerating/redifferentiating renal tubular cell is regulated
by the expression of a number of luminal membrane
molecules, including hyaluronic acid, osteopontin, their
transmembrane receptor protein CD44, and p38 mitogen-
activated protein kinase.130,133–137 In addition, several other
molecules expressed in the renal tubular apical membrane
such as Annexin-II138 and an acidic fragment of nucleolin-
related protein139 have been proposed as active binding
protein regions for calcium oxalate crystals. The clinical
implications of this experimental evidence are progressively
emerging in the field.
In addition, the increased incidence of tubular nephro-
calcinosis in preterm infants may possibly occur from
exposure of differentiating renal tubular epithelial cells
following crystalluria caused by furosemide treatment.140,141
Moreover, tubular nephrocalcinosis has been seen in a large
number of renal allografts, suggesting that ischemic injury
resulting in increased expression of hyaluronic acid and
osteopontin precedes crystal retention.142,143 From the above
discussion, one can conclude that under normal conditions,
crystals do not adhere to renal tubular epithelial cells and are
readily excreted in the urine. However, with antecedent renal
tubular epithelial damage and during the process of renal
tubular repair,144–146 specific crystal-binding proteins are
expressed at the apical surface of the renal epithelial cell,
predisposing crystal adhesion and possibly stone formation.
Whether this process has a pathogenic function in many
clinical conditions associated with tubular nephrocalcinosis
and nephrolithiasis deserves intense future investigation.130
CONCLUSION
Kidney stone disease remains a major public health burden.
Its pathophysiologic mechanisms are complex, mainly
because it is a polygenic disorder, and it involves an intricate
interaction between the gut, kidney, and bone. In addition,
an exact animal model to recapitulate the human disease has
not yet been defined. Despite these limitations, our
comprehension of UA stone formation’s link to insulin
resistance and renal lipotoxicity, the underlying mechanisms
of intestinal oxalate transport, the role of renal papillary
plaque in idiopathic calcium oxalate stone formation and
renal tubular crystal bindings, has advanced significantly over
the past decade. These elucidations can potentially lead us to
the development of novel drugs targeting basic metabolic
abnormalities that abrogate stone formation.
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